In the closing of the recent trading day, Moderna (MRNA) stood at $30.41, denoting a -2.38% move from the preceding trading day.

Cwm LLC grew its position in Moderna, Inc. (NASDAQ: MRNA) by 50.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 390,333 shares of the company's stock after purchasing an additional 130,200 shares during the quarter. Cwm LLC owned approximately 0.10% of

Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it's been on the rise. This other biotech has proven itself as a long-term winner.

The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.

Stocks are recovering from morning losses, with all three major indexes now eyeing four-straight wins

Top large-cap gainers for Dec. 15-19 were led by Rivian, Moderna, and BioMarin, rising on product/software updates, vaccine funding news, and a major acquisition deal, with Rocket Lab, Affirm, and cruise names also jumping on strong contracts, partnerships, and earnings.

Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.

Moderna's earnings and stock price climbed during early pandemic days -- that's as demand for the company's coronavirus vaccine soared. Since, the company has faced various challenges that have weighed on investors' appetite for the stock.

Funding support from outside groups could be opening a new chapter for Moderna (MRNA) as the company advances its bird flu vaccine program amid a shifting US re

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.